glp 1 trapezoid Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD Glucagon-Like Peptide-1 Based Therapies: A

Back in 2025, researchers from the ATTAIN-1 trial found that taking orforglipron for 72 weeks was associated with significant benefits in patients with weight-related medical problems without diabetes

Both GHRH analogs and ghrelin mimetics were previously employed in our laboratory studies to evaluate pulsatile secretion of a particular hormone and its receptor interaction, and used together they helped to explore mechanisms related to them more broadly than did use of any single compounds in the research that were found within a database in PubMed

fast Download PDF Now- 20262029 pipeline snapshot: Novo Nordisk CagriSema (GLP-1 + amylin) Filing 2026 Lilly Orforglipron (oral GLP-1) + Retatrutide (triple agonist) Launch window 20262027 Amgen Maritide (GLP-1 + GIP) 20272028 target BI / Zealand Survodutide (GLP-1 + glucagon) 2027 Altimmune Pemvidutide (GLP-1 + glucagon) 2027 Roche CT-388 / Petrelintide possible 2029 And one notable miss: Pfizer Danuglipron discontinued Clear trend: Single GLP-1 dual triple agonists Competition is shifting from: Who has a GLP-1? to Who has the most effective combination biology? Execution risk is still real but the bar for efficacy is moving quickly

[7] [8] By activating the GLP-1 receptor, retatrutide promotes insulin secretion, reduces appetite, and slows gastric emptying

BB: In 2023, she published her first book, The Galveston Diet